Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aro Biotherapeutics

News headline image
Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics to Present Clinical Update from its Pompe Disease Program at the 22nd Annual WORLDSymposium
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Completes Enrollment in Phase 1b Trial of Targeted siRNA Therapy, ABX1100, in Late-Onset Pompe Disease (LOPD)
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Announces U.S. FDA Clearance of IND Application for ABX1100 for Potential Treatment of Late-Onset Pompe Disease (LOPD)
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD)
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Opens Enrollment of Phase 1b Trial of ABX1100 in Patients with Late-Onset Pompe Disease (LOPD)
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics to Present Updates on ABX1100, a CD71 Centyrin – Gys1 siRNA Conjugate for the Treatment of Pompe Disease at the 20th Annual WORLD Symposium 2024​ Meeting
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Secures $41.5M Series B Financing
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Disease
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics to Highlight Therapeutic Potential of Centyrin Oligonucleotide Conjugates at Upcoming Industry Conferences
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Expands Leadership Team with Appointment of Sukumar Sakamuri, Ph.D. as Chief Technology Officer
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Appoints Mittie Doyle, MD, FACR as Chief Medical Officer
From Aro Biotherapeutics
Via Business Wire
News headline image
Aro Biotherapeutics Expands Leadership Team and Plans Move to New Philadelphia Headquarters to Drive Next Phase of Growth
From Aro Biotherapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.